Which of the following is not mediated by antibodies?
a. type I hypersensitivity
b. type II hypersensitivity
c. type III hypersensitivity
d. type IV hypersensitivity
e. None of the above
d. type IV hypersensitivity
a. nickel
b. recombinant human insulin
c. plant oil
d. mouse-derived monoclonal antibody
e. helminth infection
d. mouse-derived monoclonal antibody
a. type I and II
b. type I and III
c. type I and IV
d. type II and III
e. type II and IV
b. type I and III
a. It is expressed on the surface of mast cells and basophils.
b. It is a low-affinity receptor involved in type I hypersensitivity reactions.
c. It binds to IgE in the absence of antigen.
d. It is a membrane-bound tetramer.
e. It contains signaling components that re activated following antigen cross-linking.
b. It is a low-affinity receptor involved in type I hypersensitivity reactions.
a. cathepsin G
b. CR2
c. eotaxin
d. major basic protein
e. ADAM10
e. ADAM10
a. heparin
b. eicosanoids
c. neutral proteases
d. histamine
e. TNF-alpha
b. eicosanoids
a. platelet-activating factor, leukotrienes, and prostaglandins
b. cathepsin G
c. chymase
d. histamine
e. carboxypeptidase
a. platelet-activating factor, leukotrienes, and prostaglandins
a. chemotaxis of neutrophils, eosinophils, and effector T cells
b. growth factor secretion
c. smooth muscle contraction
d. connective tissue remodeling
e. All of the above are mediated by mast cells.
e. All of the above are mediated by mast cells.
a. TNF-alpha: immediate release from mast cells
b. mucosal mast cell production: T-cell immunodeficiencies
c. connective tissue mast cells: chymotryptase
d. lipid mediator: prostaglandins
e. leukotrienes: increase vascular permeability
b. mucosal mast cell production: T-cell immunodeficiencies
a. chemotaxis of neutrophils
b. increased vascular permeability
c. vasodilation
d. chemotaxis of macrophages
d. chemotaxis of macrophages
a. ADAM10
b. experimental anti-IgE
c. aspirin (acetyl salicylate)
d. chymotryptase
e. ADAM33
c. aspirin (acetyl salicylate)
a. IL-4
b. IL-13
c. TNF-alpha
d. FcgammaRII
e. IL-5
e. IL-5
a. T-independent antigens
b. superantigens
c. subunit vaccines
d. attenuated vaccines
e. allergens
e. allergens
a. The B cell would switch again to IgG3.
b. The B cell would remain in the germinal center but would not differentiate into a plasma cell.
c. The B cell would die by apoptosis.
d. The IgE produced would have low affinity for antigen.
e. The IgG produced would have low affinity for antigen.
d. The IgE produced would have low affinity for antigen.
a. plant pollen
b. metals
c. animal dander
d. mold spores
e. house dust mite feces
b. metals
a. cyclooxygenase
b. carboxypeptidase
c. metalloprotease
d. lipoxygenase
e. peroxidase
a. cyclooxygenase
a. an immediate type I allergic response
b. a late-phase type I allergic response
c. a late-phase type IV allergic response
d. an immediate type III allergic response
e. a late-phase type III allergic response
a. an immediate type I allergic response
a. measure wheal-and-flare diameter after intradermal injection of allergen
b. measure Arthus reaction diameter after intradermal injection of allergen
c. inject a controlled amount of allergen intradermally and observe urticaria
d. measure peak expiratory flow rate (PEFR) following inhalation of allergen
e. measure eosinophils in nasal secretions following inhalation of allergen
d. measure peak expiratory flow rate (PEFR) following inhalation of allergen
a. IgG4:IgE
b. IgE:IgM
c. IgA:IgM
d. IgG1:IgG4
e. IgE:IgG4
e. IgE:IgG4
a. subcutaneous injection of epinephrine
b. intravenous injection of corticosteroids
c. intravenous injection of antihistamine
d. intravenous injection of antibiotics
e. intravenous injection of a nonsteroidal anti-inflammatory drug
a. subcutaneous injection of epinephrine